Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy in Relapsed/Refractory Adult Acute Lymphoblastic Leukemia

Next Previous
Trial Profile

Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy in Relapsed/Refractory Adult Acute Lymphoblastic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cytarabine; Dexamethasone; Doxorubicin; Methotrexate; Pegaspargase; Pegaspargase; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Jan 2018 Status changed from discontinued to active, no longer recruiting.
    • 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Feb 2017 Planned End Date changed from 1 Jul 2017 to 30 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top